At baseline (n = 27) | After intervention (n = 27) | P-value | |
---|---|---|---|
Demographic and clinical characteristics | |||
Age (years) | 30.8 [26.2–33.1] | 31.1 [26.4–33.3] | |
Sex ratio (M/F) | 15 / 12 | ||
Body mass index (kg/m2) | 20.3 [19.0–22.8] | 22.3 [20.6–24.7] | 0.0003 |
Tobacco users, n (%) | 13 (48) | ||
Retinopathy, n (%) | 4 (15) | ||
Nephropathy, n (%) | |||
Stage 0 | 26 (96) | ||
Stage 1 | 0 (0) | 13 (48) | 1.0 |
Biological characteristics | |||
HbA1c (mmol/mol) | 101 [88–118] | 65 [49–75] | < 0.00001 |
HbA1c (%) | 11.4 [10.2–12.9] | 8.1 [6.6–9.0] | < 0.00001 |
eGFR (ml.min−1.1.73 m−2) | 126 [119–132] | 124 [116–128] | 0.06 |
Plasma urea (mmol/L) | 5.10 [4.40–6.60] | 5.20 [4.35–5.95] | 0.82 |
Serum triglycerides (mmol/L) | 0.94 [0.86–1.57] | 0.95 [0.82–1.15] | 0.10 |
Serum total cholesterol (mmol/L) | 4.50 [3.80–5.12] | 4.40 [4.00–4.70] | 0.54 |
Serum HDL-cholesterol (mmol/L) | 1.27 [1.08–1.51] | 1.44 [1.23–1.76] | 0.002 |
Serum LDL-cholesterol (mmol/L) | 2.55 [2.09–3.04] | 2.40 [1.87–2.91] | 0.12 |
Plasma MPO (µg/L) | 85.5 [68.8–104.3] | 78.9 [60.3–104.3] | 0.51 |
HDL composition | |||
HDL-proteins (% HDL total weight) | 43.4 [42.0–44.4] | 43.5 [42.2–44.8] | 0.73 |
HDL-apoAI (% HDL total weight) | 31.3 [29.7–31.9] | 31.0 [29.9–31.8] | 0.60 |
HDL-phospholipids (% HDL total weight) | 32.9 [32.3–35.1] | 33.6 [32.4–34.6] | 0.35 |
HDL-esterified cholesterol (% HDL total weight) | 18.3 [17.1–20.0] | 18.7 [17.4–20.2] | 0.23 |
HDL-triglycerides (% HDL total weight) | 4.23 [3.53–4.77] | 3.59 [2.74–4.19] | 0.011 |
HDL-esterified cholesterol/HDL-triglycerides | 8.24 [5.94–9.44] | 9.28 [7.55–13.34] | 0.005 |
HDL-free cholesterol (% HDL total weight) | 3.42 [2.99–3.84] | 3.42 [3.22–3.99] | 0.051 |